|
 The company, which went public on the U.S. Nasdaq in October last
year, said the investors would purchase about $139 million in
ordinary shares and $112 million in 4-year mandatory convertible
notes.
The investors are in for an early reckoning because BioNTech has
said it expects first clinical data on its COVID-19 vaccine
development programme known as BNT162 this month or in July.
The transaction would increase the number of shares outstanding by
2.6 million from 226.8 million shares as per end of March, resulting
in a combined stake of 1.1% for the investor group once all notes
are converted.
BioNTech, which is also working on personalised cancer vaccines,
would not say how much of the total is attributed to Singapore state
investment company Temasek.
BioNTech and its partner Pfizer launched testing programmes
involving humans in April and May.
[to top of second column] |
Domestic rival vaccine developer CureVac, in which the German government is
taking a 23% stake, is planning an initial public offering in the United States
next month. U.S. peer Translate Bio has attracted France's Sanofi as an investor
in a deal worth as much as $2 billion.
BioNTech, which awarded the rights to BNT162 in China to Shanghai Fosun under a
March collaboration deal, is competing with CureVac as well as U.S. biotech
firms Moderna and Translate Bio in the race to develop messenger-RNA vaccines.
These molecules act as recipes designed to instruct human cells to produce
antigen proteins. That would allow the immune system to develop an arsenal
against future coronavirus infections.
(Reporting by Ludwig Burger; editing by Thomas Seythal and Emelia
Sithole-Matarise)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
